Saturday, December 4, 2021

AstraZeneca blocks Advent's $7.6-bn buyout of Swedish Orphan Biovitrum

The UK drugmaker's opposition meant the offer fell short of the 90 per cent threshold needed for approval

from Today's Paper https://ift.tt/2ZPOdNG
via

No comments:

Post a Comment

If you have any doubts please let me know!

India's low score on GVC a starting point for recovery from pandemic: AIIB

India rated 7.4 percentage points below the average global value chain participation rate for emerging economies from Today's Paper ht...